Journal of Gastric Cancer最新文献

{"title":"Mediastinal Lymph Node Dissection in Gastroesophageal Junction Adenocarcinoma.","authors":"Jin-Jo Kim","doi":"10.5230/jgc.2023.23.e3","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e3","url":null,"abstract":"<p><p>Currently, the prevalence of gastroesophageal junction adenocarcinoma (GEJAC) is increasing in both Asian and Western countries, although the increasing rate in Asian countries is much slower than in Western countries. With these current trends, concerns regarding the surgical treatment method are also increasing among gastrointestinal surgeons. However, the surgical treatment for GEJAC has been a controversial issue for a long time due to the relative scarcity of this tumor and its characteristics from its borderline location. Recently, a large-scale prospective study of this tumor has been conducted in Japan, and the results are now available. The results of this study will be helpful for understanding this tumor. In this article, the pattern of lymph node metastasis of GEJAC is reviewed, and the extent and method of lymph node dissection for this tumor are discussed and proposed based on the review.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"171-181"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/e9/jgc-23-171.PMC9911615.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9306303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination.","authors":"Sun Young Rha, Hyun Cheol Chung","doi":"10.5230/jgc.2023.23.e6","DOIUrl":"10.5230/jgc.2023.23.e6","url":null,"abstract":"<p><p>Gastric cancer is heterogeneous in morphology, biology, genomics, and treatment response. Alterations in human epidermal growth factor receptor 2 (HER2) overexpression, microsatellite instability (MSI) status, programmed death-ligand 1 (PD-L1) levels, and fibroblast growth factor receptor 2 (FGFR2) can be used as biomarkers. Since the combination of fluoropyrimidine/platinum plus trastuzumab that was investigated in the ToGA trial was approved as a standard of care in HER2-positive patients in 2010, no other agents showed efficacy in the first- (HELOISE, LOGiC, JACOB trials) and second- (TyTAN, GATSBY, T-ACT trials) line treatments. Despite the success in treating breast cancer, various anti-HER2 agents, including a monoclonal antibody (pertuzumab), an antibody-drug conjugate (ADC; trastuzumab emtansine [T-DM1]), and a small molecule (lapatinib) failed to translate into clinical benefits until the KEYNOTE-811 (first-line) and DESTINY-Gastri01 (≥second-line) trials were conducted. The incorporation of HER2-directed treatment with immune checkpoint inhibitors in the form of a monoclonal antibody or ADC is now approved as a standard treatment. Despite the promising results of new agents (engineered monoclonal antibodies, bi-specific antibodies, fusion proteins, and small molecules) in the early phase of development, the management of HER2-positive gastric cancer requires further optimization to achieve precision medicine with a chemotherapeutic backbone. Treatment resistance is a complex process that can be overcome using a combination of chemotherapy, targeted agents, and immune checkpoint inhibitors, including novel agents. HER2 status must be reassessed in patients undergoing anti-HER2 treatment with disease progression after the first-line treatment. As a general guideline, patients who need systemic treatment should receive chemotherapy plus targeted agents, anti-angiogenic agents, immune checkpoint inhibitors, or their combinations.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"224-249"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/61/jgc-23-224.PMC9911617.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10280142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 Pandemic on Gastric Cancer Screening in South Korea: Results From the Korean National Cancer Screening Survey (2017-2021).","authors":"Kyeongmin Lee, Mina Suh, Jae Kwan Jun, Kui Son Choi","doi":"10.5230/jgc.2022.22.e36","DOIUrl":"10.5230/jgc.2022.22.e36","url":null,"abstract":"<p><strong>Purpose: </strong>The coronavirus disease 2019 (COVID-19) pandemic has significantly disrupted cancer screening services worldwide. We aimed to measure the impact of COVID-19 on gastric cancer screening rates based on age, sex, household income, and residential area.</p><p><strong>Materials and methods: </strong>We analyzed data from the Korean National Cancer Screening Survey from 2017 to 2021 for adults aged 40-74 years. We evaluated the gastric cancer screening rate within two years in accordance with the National Cancer Screening Program protocol recommendations and that within the previous year. We compared the trends in the pre- and post-COVID-19 outbreak periods.</p><p><strong>Results: </strong>Before the COVID-19 outbreak, there was little change in the gastric cancer screening rates until 2019. After the COVID-19 outbreak, the screening rate as per recommendation decreased from 70.8% in 2019 to 68.9% in 2020 and that for one year decreased from 32.7% in 2019 to 27.2% in 2020. However, as the COVID-19 pandemic continued after 2020, both gastric cancer screening rates as per recommendations and for one year rebounded. Although a similar trend was observed for the upper endoscopy screening rate, the upper gastrointestinal series screening rate decreased from 7.8% in 2020 to 3.1% in 2021. During the pandemic, the screening rate decreased among younger adults (40-49), those residing in metropolitan regions, and those with high incomes.</p><p><strong>Conclusions: </strong>Despite a decline in gastric cancer screening rate during the COVID-19 pandemic, the rate surged in 2021. Further studies are needed to estimate the impact of cancer screening delays on future cancer-related mortalities.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"22 4","pages":"264-272"},"PeriodicalIF":3.2,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/6a/jgc-22-264.PMC9633925.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40459992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Findings and Treatment of Gastric Neoplasms in Familial Adenomatous Polyposis.","authors":"Chihiro Sato,&nbsp;Kazuya Takahashi,&nbsp;Hiroki Sato,&nbsp;Takumi Naruse,&nbsp;Nao Nakajima,&nbsp;Masafumi Takatsuna,&nbsp;Ken-Ichi Mizuno,&nbsp;Satoru Hashimoto,&nbsp;Manabu Takeuchi,&nbsp;Junji Yokoyama,&nbsp;Masaaki Kobayashi,&nbsp;Shuji Terai","doi":"10.5230/jgc.2022.22.e30","DOIUrl":"https://doi.org/10.5230/jgc.2022.22.e30","url":null,"abstract":"<p><strong>Purpose: </strong>Gastric neoplasia is a common manifestation of familial adenomatous polyposis (FAP). This study aimed to elucidate the clinical characteristics, endoscopic features including fundic gland polyposis (FGPsis), and treatment outcomes of gastric neoplasms (GNs) in patients with FAP.</p><p><strong>Materials and methods: </strong>A total of 35 patients diagnosed with FAP, including nine patients from four pedigrees who underwent esophagogastroduodenoscopy (EGD), were investigated regarding patient characteristics, GN morphology, and treatment outcomes.</p><p><strong>Results: </strong>Twenty-one patients (60.0%) had 38 GNs; 33 (86.8%) and 5 (13.2%) were histologically diagnosed with adenocarcinoma and adenoma, respectively. There were no specific patient characteristics related to GNs. Nodule-type GNs were more prevalent in patients with FGP than without (52.2% vs. 0.0%, P=0.002) in the upper body of the stomach. Conversely, depressed-type GNs were fewer in patients with FGPsis than in those without (13.0% vs. 73.3%, P<0.001). Slightly elevated-type GNs were observed in both groups (34.8% vs. 20.0%, P=0.538). Even within pedigrees, the background gastric mucosa and types of GNs varied. In total, 24 GNs were treated with endoscopic submucosal dissection (ESD) and eight with endoscopic mucosal resection (EMR). EMR was selected for GNs with FGPsis because of the technical difficulty of ESD, resulting in a lower en bloc resection rate (62.5% vs. 100%, P=0.014).</p><p><strong>Conclusions: </strong>Our study indicates the necessity of routine EGD surveillance in patients diagnosed with FAP. Notably, the morphology and location of GNs differed between patients with and without FGPsis. Endoscopic treatment and outcomes require more attention in cases of FGPsis.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"22 4","pages":"381-394"},"PeriodicalIF":2.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/a0/jgc-22-381.PMC9633932.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40657426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extragastric Metastasis of Early Gastric Cancer After Endoscopic Submucosal Dissection With Lymphovascular Invasion and Negative Resected Margins.","authors":"Han Myung Lee,&nbsp;Yoonjin Kwak,&nbsp;Hyunsoo Chung,&nbsp;Sang Gyun Kim,&nbsp;Soo-Jeong Cho","doi":"10.5230/jgc.2022.22.e27","DOIUrl":"https://doi.org/10.5230/jgc.2022.22.e27","url":null,"abstract":"<p><strong>Purpose: </strong>Lymphovascular invasion is a criterion for non-curative resection in patients who have undergone endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). We aimed to determine the rate of extragastric metastasis (EGM) and identify the predictors of EGM in patients with negative resection margins (R0 resection) and lymphovascular invasion in post-ESD pathology.</p><p><strong>Materials and methods: </strong>A total of 2,983 patients underwent ESD for EGC. Among them, 110 had a pathology of R0 resection and positive lymphovascular invasion. Patients underwent additional gastrectomy (n=63) or further follow-up without gastrectomy (n=47).</p><p><strong>Results: </strong>The 110 patients were assigned to one of the 3 groups according to ESD indications based on post-ESD pathology. The first group satisfied the absolute indication for ESD (n=18), the second group satisfied the expanded indications for ESD (n=34), and the last group satisfied the beyond indication (n=58). The number of occurrences of EGM in each group was 1 (5.6%), 3 (8.8%), and 3 (5.2%), respectively. The logistic regression analysis adjusted for age, sex, tumor size, and indication for ESD, showed that larger tumor size was associated with EGM (odds ratio, 1.76; 95% confidence interval, 1.00-3.10; P=0.048). In contrast, ESD indication criteria did not affect EGM (P=0.349).</p><p><strong>Conclusions: </strong>Tumor size was the only predictive indicator for EGM in patients who underwent R0 resection and lymphovascular invasion on post-ESD pathology. Even patients with pathology corresponding to the absolute indication criteria of ESD had lymphovascular invasion, which means that they require additional gastrectomy due to the risk of EGM.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"22 4","pages":"339-347"},"PeriodicalIF":2.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/64/jgc-22-339.PMC9633933.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40657422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary Biomarkers for the Noninvasive Detection of Gastric Cancer.","authors":"Dehong Li,&nbsp;Li Yan,&nbsp;Fugui Lin,&nbsp;Xiumei Yuan,&nbsp;Xingwen Yang,&nbsp;Xiaoyan Yang,&nbsp;Lianhua Wei,&nbsp;Yang Yang,&nbsp;Yan Lu","doi":"10.5230/jgc.2022.22.e28","DOIUrl":"https://doi.org/10.5230/jgc.2022.22.e28","url":null,"abstract":"<p><p>Gastric cancer (GC) is associated with high morbidity and mortality rates. Thus, early diagnosis is important to improve disease prognosis. Endoscopic assessment represents the most reliable imaging method for GC diagnosis; however, it is semi-invasive and costly and heavily depends on the skills of the endoscopist, which limit its clinical applicability. Therefore, the search for new sensitive biomarkers for the early detection of GC using noninvasive sampling collection methods has attracted much attention among scientists. Urine is considered an ideal biofluid, as it is readily accessible, less complex, and relatively stable than plasma and serum. Over the years, substantial progress has been made in screening for potential urinary biomarkers for GC. This review explores the possible applications and limitations of urinary biomarkers in GC detection and diagnosis.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"22 4","pages":"306-318"},"PeriodicalIF":2.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/a4/jgc-22-306.PMC9633929.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40657420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Pathology of Gastric Cancer.","authors":"Moonsik Kim,&nbsp;An Na Seo","doi":"10.5230/jgc.2022.22.e35","DOIUrl":"https://doi.org/10.5230/jgc.2022.22.e35","url":null,"abstract":"<p><p>Gastric cancer (GC) is one of the most common lethal malignant neoplasms worldwide, with limited treatment options for both locally advanced and/or metastatic conditions, resulting in a dismal prognosis. Although the widely used morphological classifications may be helpful for endoscopic or surgical treatment choices, they are still insufficient to guide precise and/or personalized therapy for individual patients. Recent advances in genomic technology and high-throughput analysis may improve the understanding of molecular pathways associated with GC pathogenesis and aid in the classification of GC at the molecular level. Advances in next-generation sequencing have enabled the identification of several genetic alterations through single experiments. Thus, understanding the driver alterations involved in gastric carcinogenesis has become increasingly important because it can aid in the discovery of potential biomarkers and therapeutic targets. In this article, we review the molecular classifications of GC, focusing on The Cancer Genome Atlas (TCGA) classification. We further describe the currently available biomarker-targeted therapies and potential biomarker-guided therapies. This review will help clinicians by providing an inclusive understanding of the molecular pathology of GC and may assist in selecting the best treatment approaches for patients with GC.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"22 4","pages":"273-305"},"PeriodicalIF":2.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/1f/jgc-22-273.PMC9633931.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40657423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>PLK2</i> Single Nucleotide Variant in Gastric Cancer Patients Affects miR-23b-5p Binding.","authors":"Pia Pužar Dominkuš,&nbsp;Aner Mesic,&nbsp;Petra Hudler","doi":"10.5230/jgc.2022.22.e31","DOIUrl":"https://doi.org/10.5230/jgc.2022.22.e31","url":null,"abstract":"<p><strong>Purpose: </strong>Chromosomal instability is a hallmark of gastric cancer (GC). It can be driven by single nucleotide variants (SNVs) in cell cycle genes. We investigated the associations between SNVs in candidate genes, <i>PLK2</i>, <i>PLK3</i>, and <i>ATM,</i> and GC risk and clinicopathological features.</p><p><strong>Materials and methods: </strong>The genotyping study included 542 patients with GC and healthy controls. Generalized linear models were used for the risk and clinicopathological association analyses. Survival analysis was performed using the Kaplan-Meier method. The binding of candidate miRs was analyzed using a luciferase reporter assay.</p><p><strong>Results: </strong>The <i>PLK2</i> <b>C</b>_rs15009-<b>C</b>_rs963615 haplotype was under-represented in the GC group compared to that in the control group (P_corr=0.050). Male patients with <i>the PLK2</i> rs963615 CT genotype had a lower risk of GC, whereas female patients had a higher risk (P=0.023; P=0.026). The <i>PLK2</i> rs963615 CT genotype was associated with the absence of vascular invasion (P=0.012). The <i>PLK3</i> rs12404160 AA genotype was associated with a higher risk of GC in the male population (P=0.015). The <i>ATM</i> <b>T</b>_rs228589-<b>A</b>_rs189037-<b>G</b>_rs4585 haplotype was associated with a higher risk of GC (P<0.001). The <i>ATM</i> rs228589, rs189037, and rs4585 genotypes TA+AA, AG+GG, and TG+GG were associated with the absence of perineural invasion (P=0.034). <i>In vitro</i> analysis showed that the cancer-associated miR-23b-5p mimic specifically bound to <i>the PLK2</i> rs15009 G allele (P=0.0097). Moreover, low miR-23b expression predicted longer 10-year survival (P=0.0066) in patients with GC.</p><p><strong>Conclusions: </strong><i>PLK2</i>, <i>PLK3</i>, and <i>ATM</i> SNVs could potentially be helpful for the prediction of GC risk and clinicopathological features. <i>PLK2</i> rs15009 affects the binding of miR-23b-5p. MiR-23b-5p expression status could serve as a prognostic marker for survival in patients with GC.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"22 4","pages":"348-368"},"PeriodicalIF":2.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/57/jgc-22-348.PMC9633926.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40657425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study.","authors":"Xin Zhang,&nbsp;Haoran Huo,&nbsp;Yanan Nie,&nbsp;Jiadong Xue,&nbsp;Zengjiang Yuan,&nbsp;Zhenyi Zhang","doi":"10.5230/jgc.2022.22.e33","DOIUrl":"https://doi.org/10.5230/jgc.2022.22.e33","url":null,"abstract":"<p><strong>Purpose: </strong>Treatment options are limited after the failure of first-and second-line treatments in patients with HER2⁺ metastatic gastric cancer (mGC). The present study aimed to explore the efficacy, safety, and prognostic factors of apatinib efficacy as a third-line therapy for patients with human epithelial growth factor receptor 2-positive (HER2⁺) mGC.</p><p><strong>Materials and methods: </strong>A total of 59 HER2⁺ mGC patients who received apatinib as third-line therapy were retrospectively enrolled in this two-center, single-arm, cohort study; the clinical response, survival data, and adverse events were retrieved.</p><p><strong>Results: </strong>The median progression-free survival (PFS) was 5.2 months (95% confidence interval [CI], 3.9-6.5), and the median overall survival (OS) was 8.2 months (95% CI, 6.6-9.8) Furthermore, forward stepwise multivariate Cox regression analysis showed that a higher Eastern Cooperative Oncology Group performance status score and multiple metastases were independently correlated with decreased PFS and OS (both P<0.05). The main adverse events were leukopenia (45.8%), hypertension (44.1%), thrombocytopenia (39.0%), hand-foot syndrome (37.3%), and elevated transaminase (33.9%). Grade 3 adverse events mainly included hypertension (5.1%) and neutropenia (5.1%); grade 4 adverse events did not occur.</p><p><strong>Conclusions: </strong>Apatinib is efficient and well tolerated in patients with HER2⁺ mGC as a third-line treatment, suggesting that it may be a candidate of choice for these patients.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"22 4","pages":"408-417"},"PeriodicalIF":2.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/01/jgc-22-408.PMC9633934.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40658920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision for Safe Discharge After Gastric Cancer Surgery: The Finale of Enhanced Recovery After Surgery Program.","authors":"Yoon Young Choi","doi":"10.5230/jgc.2022.22.e34","DOIUrl":"https://doi.org/10.5230/jgc.2022.22.e34","url":null,"abstract":"https://jgc-online.org Since the first successful gastrectomy by Theodor Billroth in 1881 [1], surgery has been the main treatment option for gastric cancer, which is one of the main causes of death in the Republic of Korea [2]. Understanding the biology of cancer and anatomy of the stomach and surrounding structures [3], the developed surgical technique and equipment [4], and improved perioperative care [5] help improve the surgical outcomes after gastrectomy for gastric cancer. The related mortality has dramatically decreased from 69% in the 1880s to less than 1% recently [1,6]. The hospital stay has also decreased from 22 days reported in the first cases by Billroth to 7 days in recent cases [6], and the minimally invasive surgery reduced it to even less than 5 days [7]. The enhanced recovery after surgery (ERAS), a multimodal, multidisciplinary approach to surgical treatment, is the center of this improvement.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"22 4","pages":"261-263"},"PeriodicalIF":2.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/fa/jgc-22-261.PMC9633927.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40459991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}